Please Wait...

Luc Bracoud

Translation skills

Main profile

Luc Bracoud, MSc
Director, Neuroscience

Luc Bracoud graduated from Ecole Centrale Lyon in 2001. He joined Theralys in 2002, which was later acquired by BioClinica (formerly known as Bio-Imaging Technologies) as a software developer and medical image processing engineer. He also served as a project manager, and has been involved in various large multi-center clinical trials mainly in Stroke, MS and AD, as well as Gaucher Disease. His main image processing activities are related to spatial registration, segmentation, atrophy quantification, perfusion imaging, diffusion and diffusion tensor imaging.

Authored Publications

Serge Gauthier, MD, Howard H Feldman, MD, Lon S Schneider, MD, Gordon K Wilcock, DM, Giovanni B Frisoni, MD, Jiri H Hardlund, MD, Hans J Moebius, MD, Peter Bentham, MBChB, Karin A Kook, PhD, Damon J Wischik, PhD, Bjoern O Schelter, Charles S Davis, PhD, Roger T Staff, PhD, Luc Bracoud, MSc, Kohkan Shamsi, MD, John M D Storey, Charles R Harrington, PhD, Claude M Wischik, MBBS.  Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. 15 November 2016. DOI: http://dx.doi.org/10.1016/S0140-6736(16)31275-2.

Coric V, Salloway S, H. van Dyck C, Dubois B, Andreasen N, Brody M, Curtis C, Soininen H, Thein S, Shiovitz T, Pilcher G, Ferris S, Colby S, Kerselaers W, Dockens R, Soares H, Kaplita S, Luo F, Pachai C, Bracoud L, Mintun M, Grill JD, Marek K, Seibyl J, Cedarbaum JM, Albright C, Feldman HH, Berman RM. Targetting Prodromal Alzheimer Disease with Avagacestat A Randomized Clinical Trial.  JAMA Neurol 2015, Sept 28. [Epub ahead of print]

Sibon I, Tourdias T, Felix S, Asselineau J, Bracoud L, Vivot A, Rouanet F, Renou P, Orgogozo JM, Dousset V. Magnetisation transfer parameters and stroke outcome. J Clin Neurosci. 2015 Jun;22(6):1012-7.

Kufner A, Wouters A, Bracoud L, Laage R, Schneider A, Schäbitz W, Hermier M, Thijs V, Fiebach JB, on behalf of the AXIS2 investigators.  Infarct Volume-Based Subgroup Selection in Acute Ischemic Stroke Trials. Stroke, May 2015.

Opherk C, Gonik M, Duering M, Malik R, Jouvent E, Hervé D, Adib-Samii P, Bevan S, Pianese L, Silvestri S, Dotti MT, De Stefano N, Liem M, Boon EM, Pescini F, Pachai C, Bracoud L, Müller-Myhsok B, Meitinger T, Rost N, Pantoni L, Oberstein SL, Federico A, Ragno M, Markus HS, Tournier-Lasserve E, Rosand J, Chabriat H, Dichgans M. Genome-Wide Genotyping Demonstrates a Polygenic Risk Score Associated With White Matter Hyperintensity Volume in CADASIL. Stroke. 2014 Feb 27. [Epub ahead of print]

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Integration of #eTMF and #CTMS eliminates redundancies, improves workflows & enables greater study control. Join th… https://t.co/1917MtlAsA
Bioclinica (4 days ago)
Thinking of building a study in-house? Here are the 5 things you should think about before starting a DIY study bui… https://t.co/xzZWQOm49S
Bioclinica (2 weeks ago)
Integration of #eTMF and #CTMS eliminates redundancies, improves workflows & enables greater study control. Join th… https://t.co/Hoqf18zcPF
Bioclinica (2 weeks ago)
Your #IRT should not be the limiting factor during study start-up. The core features of Bioclinica's IRT agile plat… https://t.co/kitdsWvJ2S
Bioclinica (2 weeks ago)
Presenting Bioclinica CTMS: a rapid startup #CTMS that takes 2 weeks to implement, rather than months. Bioclinica C… https://t.co/tclYFoJx2z
Bioclinica (3 weeks ago)
Improve doc & study mgmt. across all studies by integrating #eTMF & #CTMS. In this webinar, Bioclinica &… https://t.co/UyoQyJVDah
Bioclinica (3 weeks ago)